Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
André Fernandes, Charlotte MacAulay, Abdul R Khater, Hannah Matthews, Ganesh Mohrir, Christopher Lodge · 2025
Read Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists by André Fernandes, Charlotte MacAulay, Abdul R Khater, Hannah Matthews, Ganesh Mohrir, Christopher Lodge (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12720054.txt.
Description
André Fernandes and co-authors pool past studies on whether GLP-1 drugs cut infection risk after joint replacement in people with obesity, in a 2025 review. Obesity raises the odds of infection around a new hip or knee joint. GLP-1 drugs bring strong weight loss and better metabolic health. Whether they help around surgery was unclear.
Eight cohort studies with more than ninety-five thousand patients met the bar, and about a fifth of them used the drugs. Drug use tied to fewer infections after hip replacement and fewer returns to hospital within 90 days. No clear link showed for knee infection or repeat surgery. Rates of clots, kidney harm, stroke, heart attack, and low blood sugar did not rise. The authors rate the proof as fair at best and call for randomized trials.
Catalog record
| CREATOR | André Fernandes, Charlotte MacAulay, Abdul R Khater, Hannah Matthews, Ganesh Mohrir, Christopher Lodge |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |